Sarah Canon Research Institute (SCRI) Oncology Partners — Nashville, Tennessee

Sarah Canon Research Institute (SCRI) Oncology Partners is a clinical research site located in Nashville, Tennessee, United States 37203.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Sarah Canon Research Institute (SCRI) Oncology Partners has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis.

Sponsors: Institut de Recherches Internationales Servier.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Nashville

Browse all research sites in Tennessee · View every site in Nashville

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Sarah Canon Research Institute (SCRI) Oncology Partners?

Sarah Canon Research Institute (SCRI) Oncology Partners has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Sarah Canon Research Institute (SCRI) Oncology Partners conducted?

Sarah Canon Research Institute (SCRI) Oncology Partners has 1 clinical trials on record, with 1 currently active. Their work covers Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis.

Is Sarah Canon Research Institute (SCRI) Oncology Partners accredited by Crixeo Clinical Trials?

Sarah Canon Research Institute (SCRI) Oncology Partners has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Sarah Canon Research Institute (SCRI) Oncology Partners?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.